Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Fish and Richardson
Argus Health
Queensland Health
Farmers Insurance

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204078

« Back to Dashboard

NDA 204078 describes BLOXIVERZ, which is a drug marketed by Avadel Legacy and is included in one NDA. It is available from two suppliers. Additional details are available on the BLOXIVERZ profile page.

The generic ingredient in BLOXIVERZ is neostigmine methylsulfate. There are eight drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the neostigmine methylsulfate profile page.
Summary for 204078
Applicant:Avadel Legacy
Ingredient:neostigmine methylsulfate
Therapeutic Class:Antimyasthenic Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 204078
Mechanism of ActionCholinesterase Inhibitors
Medical Subject Heading (MeSH) Categories for 204078
Suppliers and Packaging for NDA: 204078
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BLOXIVERZ neostigmine methylsulfate SOLUTION;INTRAVENOUS 204078 NDA BluePoint Laboratories 68001-329 N 68001-329-67
BLOXIVERZ neostigmine methylsulfate SOLUTION;INTRAVENOUS 204078 NDA Avadel Legacy Pharmaceuticals, LLC 76014-002 N 76014-002-10

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength5MG/10ML (0.5MG/ML)
Approval Date:May 31, 2013TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength10MG/10ML (1MG/ML)
Approval Date:May 31, 2013TE:APRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.